204 related articles for article (PubMed ID: 31549386)
1. Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant.
Patel JN; Hamadeh IS; Robinson M; Shahid Z; Symanowski J; Steuerwald N; Hamilton A; Reese ES; Plesca DC; Arnall J; Taylor M; Trivedi J; Grunwald MR; Gerber J; Ghosh N; Avalos B; Copelan E
Clin Pharmacol Ther; 2020 Mar; 107(3):571-579. PubMed ID: 31549386
[TBL] [Abstract][Full Text] [Related]
2. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Hamadeh IS; Klinker KP; Borgert SJ; Richards AI; Li W; Mangal N; Hiemenz JW; Schmidt S; Langaee TY; Peloquin CA; Johnson JA; Cavallari LH
Pharmacogenet Genomics; 2017 May; 27(5):190-196. PubMed ID: 28306618
[TBL] [Abstract][Full Text] [Related]
3. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
[TBL] [Abstract][Full Text] [Related]
6. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
[TBL] [Abstract][Full Text] [Related]
8. Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.
Hicks JK; Gonzalez BE; Zembillas AS; Kusick K; Murthy S; Raja S; Gordon SM; Hanna R
Pharmacogenomics; 2016 May; 17(7):663-7. PubMed ID: 27143031
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
Hu L; Huang Q; Huang S; Feng Z
Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
Kadam RS; Van Den Anker JN
Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
[TBL] [Abstract][Full Text] [Related]
12. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
[TBL] [Abstract][Full Text] [Related]
13. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
Imamura CK; Furihata K; Okamoto S; Tanigawara Y
J Clin Pharmacol; 2016 Apr; 56(4):408-13. PubMed ID: 26239045
[TBL] [Abstract][Full Text] [Related]
14. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
[TBL] [Abstract][Full Text] [Related]
15. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles.
Chung H; Lee H; Han HK; An H; Lim KS; Lee YJ; Cho JY; Yoon SH; Jang IJ; Yu KS
Drug Des Devel Ther; 2015; 9():2609-16. PubMed ID: 25999694
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
[TBL] [Abstract][Full Text] [Related]
18. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
[TBL] [Abstract][Full Text] [Related]
20. Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.
Tian X; Zhang C; Qin Z; Wang D; Yang J; Zhang X
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0020721. PubMed ID: 34152823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]